naftidrofuryl

CLINICAL USE

Vasodilator:Peripheral and cerebral vascular disease

DOSE IN NORMAL RENAL FUNCTION

Peripheral vascular disease: 100–200 mg 3 times dailyCerebral vascular disease: 100 mg 3 times daily

PHARMACOKINETICS

Molecular weight :473.6

%Protein binding :60–65

%Excreted unchanged in urine : <1 (mainly as metabolites)

Volume of distribution (L/kg) :61.5 litres

half-life – normal/ESRD (hrs) :1–2/3.5

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Unlikely to be dialysed. Dose as in normal renal function

HD :Dialysed. Dose as in normal renal function

HDF/high flux :Dialysed. Dose as in normal renal function

CAV/VVHD :Unlikely to be dialysed. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

None known

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

IV preparation was withdrawn due to increased risk of cardiac and neurological toxicity. It has also been associated with acute renal failure secondary to oxalate crystallisationnaftidrofuryl oxalate.

See how to identify renal failure stages according to GFR calculation

See how to diagnose irreversible renal disease

Home